Overview of Restylane Lyft

Property	Description
Active ingredient	Cross-linked Hyaluronan
Form	Injectable Gel (Sterile, Viscoelastic)
Pharmacological class	Soft-Tissue Augmentation Agent
General purpose	Volume restoration and structural augmentation
Origin	Derived (Non-animal stabilized Hyaluronic acid)

What Type of Injectable is Restylane Lyft?

Restylane Lyft is classified as a sterile, viscoelastic dermal filler, belonging to the high-level pharmacological class of soft-tissue augmentation agents. It is designed as an injectable gel and an implant intended for structural support beneath the skin surface. The product is administered via deep dermal, subcutaneous, or supraperiosteal injection for specific augmentation.

This injectable is structurally differentiated from agents that affect muscle movement. Instead, it provides static volume and lift by integrating into the tissue matrix. As a viscoelastic gel, its formulation is clinically recognized for its high firmness, which is essential for achieving midface contouring and providing significant structural support in areas requiring robust projection.

What is Restylane Lyft Made Of?

The active ingredient in Restylane Lyft is cross-linked Hyaluronan (Hyaluronic acid, HA), suspended in an aqueous phosphate-buffered saline solution. This substance is derived from non-animal sources, specifically generated by bacterial fermentation. This derivation method is a key factor that contributes to its overall biocompatibility.

Restylane Lyft utilizes Non-Animal Stabilized Hyaluronic Acid (NASHA) technology, a process that stabilizes the HA molecule through cross-linking. This chemical stabilization process is critical because it gives the final injectable gel greater durability and structural integrity, preventing its rapid metabolism by the body. The composition is a single-component product focused on delivering stabilized Hyaluronan.

What is the General Purpose of Restylane Lyft?

The general purpose of Restylane Lyft is volume restoration and sustained structural augmentation, typically used for correcting volume deficits in the cheeks or hands. The core mechanism principle involves the immediate physical displacement of tissue by the gel, supported by the Hyaluronan's innate capacity for hydrostatic support through binding water molecules. This results in the structural enhancement of features and is clinically recognized for improving the aesthetic transition between different facial planes.

What side effects are possible with Restylane Lyft?

Possible Side Effects and Safety Information

Restylane Lyft's official safety profile, as documented in government regulatory sources, defines potential risks based on frequency and severity. The majority of adverse events reported in clinical trials are categorized as Common and are typically local, transient reactions to the injection procedure itself. These include swelling (edema), redness (erythema), pain, tenderness, bruising (hematoma), itching, and the formation of lumps or bumps (nodules) at the site of administration. These effects are generally mild to moderate and are expected to resolve within two weeks.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions are officially documented, though categorized as Rare. The most critical safety warnings relate to the risk of unintentional intravascular injection, which may lead to severe events. Documented serious adverse reactions include temporary or permanent vision impairment or blindness, cerebral ischemia or cerebral hemorrhage (stroke), and skin necrosis related to vascular compromise. Anaphylactic shock has also been documented.

Safety is further defined by specific restrictions and contraindications. The product is contraindicated in patients with a history of severe allergies, or with hypersensitivity to lidocaine (an amide-type anesthetic) or to the trace gram-positive bacterial proteins from the manufacturing process. Use should be avoided at sites with active inflammation or infection, and caution is advised for patients taking blood thinners due to an increased risk of bruising.

Population-Specific Notes

Specific safety considerations exist for certain groups. For patients with pigmented skin, there is a higher documented incidence of post-inflammatory hyperpigmentation (skin darkening). The safety and effectiveness of the product have not been established in pediatric patients or for use during pregnancy or breastfeeding.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Restylane Lyft, a cross-linked Hyaluronan gel, does not define a traditional systemic pharmacological overdose. Instead, the focus is strictly on rare but serious adverse events associated with the unintentional injection of the product into a blood vessel (intravascular injection). This complication is classified as a life-threatening risk due to its potential for severe and potentially permanent outcomes.

Documented Manifestations and Outcomes The adverse events are linked to the compromise of the vascular, ocular, and central nervous systems, leading to:

Temporary or permanent vision impairment, including blindness.
Cerebral ischemia or hemorrhage, which can result in stroke.
Skin necrosis (tissue death) due to compromised blood flow.

Mandated Emergency Action The regulatory guidance requires immediate and prompt intervention based on specific clinical signs. Patients must receive urgent medical attention and evaluation by an appropriate specialist if they experience symptoms, including:

Sudden changes in vision.
Blanching of the skin or unusual pain at the injection site.
Signs consistent with a stroke.

Connection to the overall overdose profile The regulatory documentation defines the overdose profile based on serious adverse events arising from vascular compromise during the injection procedure. This context mandates immediate action, including the cessation of the injection upon symptom recognition and the requirement to seek prompt medical attention. The procedural measure for managing over-correction or vascular compromise is the use of the enzyme hyaluronidase for product dissolution.

Therapeutic Uses of Restylane Lyft

Restylane Lyft: Main Uses and Benefits

Restylane Lyft is an injectable dermal filler approved for specific aesthetic applications in patients over the age of 21. It functions to address volume loss and correct contour deficiencies in multiple areas. Its use is indicated for the correction of moderate to severe facial folds and wrinkles, such as the nasolabial folds (smile lines).

Additionally, the product is utilized for age-related volume loss in the midface area, including cheek augmentation. Restylane Lyft may also be employed to improve the chin profile in individuals with mild-to-moderate chin retrusion. Finally, it is intended for use in the back of the hands to correct age-related volume deficit.

Quick Facts

Therapeutic Domain: Correction of moderate to severe facial wrinkles and folds.
Key Application: Augmentation of the cheek and midface area.
Additional Use: Addressing age-related volume loss in the back of the hands.
Newer Indication: Improvement of the chin profile.

Eligibility and Restrictions for Use

Who Can and Cannot Use Restylane Lyft: Official Regulatory Information

The eligibility profile for Restylane Lyft is strictly defined by official regulatory documentation, which outlines absolute contraindications and conditional use populations.

Category	Regulatory Status (Source: FDA Labeling)
Minimum Age	Approved for use only in patients over the age of 21 years for all labeled indications.
Pediatric Use	Safety and effectiveness have not been established for patients under 18 years of age.
Pregnancy/Lactation	Safety has not been established for use during pregnancy or in breastfeeding females.

Absolute Contraindications (Must Not Use):

The product is strictly contraindicated for individuals with a history of severe allergies that manifest as anaphylaxis or a history of multiple severe allergies. Use is also prohibited in patients with a known bleeding disorder or a history of hypersensitivity to the trace amounts of gram positive bacterial proteins found in the product. The formulation containing lidocaine is further contraindicated for patients with previous hypersensitivity to local anesthetics of the amide type.

Conditional Use (Caution Required):

Restylane Lyft should be used with caution in patients who are on immunosuppressive therapy or those who have undergone therapy with anticoagulants or platelet aggregation inhibitors in the preceding three weeks. Use must be deferred at injection sites with an active inflammatory process or infection until the condition is fully resolved.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Restylane Lyft primarily addresses pharmacodynamic interactions and procedural constraints, as the cross-linked Hyaluronan active ingredient is a physical implant not subject to systemic metabolic pathways (such as CYP enzymes or transporters).

Interaction Classification	Interacting Substances/Procedures	Official Outcome or Restriction
Hemostatic Interference	Anticoagulants, Thrombolytics, Platelet Aggregation Inhibitors (e.g., Aspirin, NSAIDs)	Potential for increased bruising or bleeding at the injection site. Use with caution is advised for patients treated with these agents in the preceding three weeks.
Additive Toxicity	Other local anesthetics structurally related to amide-type anesthetics	Risk of additive systemic toxic effects due to the formulation's lidocaine component must be considered.
Non-Medicinal Modifiers	Herbal products (e.g., St. John's Wort) and high doses of Vitamin E supplements	Increases the potential for bleeding and bruising at the injection site due to their effects on coagulation.
Procedural Timing Rules	Laser treatment, Chemical peeling, Mechanical peeling	Restricted from use until the skin has healed completely after these procedures to avoid eliciting an inflammatory reaction at the implant site.
Preparation Restriction	Other products (e.g., other injectables)	The product must not be mixed with any other material prior to its implantation.

Connection to the overall interaction profile: The official regulatory documents define the product's interaction structure around minimizing procedural complications, specifically by identifying substances that increase the risk of local bleeding or bruising at the injection site. This structure mandates a timing separation from blood thinners and other active dermal therapies to avoid adverse local effects.

Mechanism of Action

How Restylane Lyft Works

The mechanism of Restylane Lyft is primarily biophysical and structural, focused on the material properties of its cross-linked Hyaluronan gel, which performs static augmentation rather than molecular pharmacological action.

Biomechanical Displacement and Load-Bearing

The injectable gel is placed into the tissue matrix space (deep dermal and subcutaneous layers), functioning as a physical implant. The gel's intrinsic high viscoelasticity and firmness (high G') cause immediate physical displacement of the native tissue, directly causing tissue elevation and providing biomechanical load-bearing resistance due to its elastic modulus. This leads to the fundamental physiological effect of structural augmentation and changes in local tissue shape.

Sustained Volume via Enzymatic Resistance

The Hyaluronan molecule is chemically modified through cross-linking (NASHA technology), a key step that chemically stabilizes the polymer. This stabilization renders the gel intrinsically resistant to rapid hydrolysis by the body's endogenous Hyaluronidase enzymes. By slowing the rate of metabolic degradation, the mechanism ensures the prolonged physical presence and structural integrity of the material, leading to a sustained duration of the volumetric effect.

Hydrostatic Support for Tissue Turgor

Hyaluronan is strongly hydrophilic, meaning its molecular structure attracts and binds a significant volume of surrounding water molecules. This osmotic action creates hydrostatic support within the implant. This passive mechanism stabilizes the total volume, contributing to the overall firmness and turgor of the augmented tissue, contributing to the implant's mechanical resistance to deformation.

Dosage and Administration Information

Restylane Lyft is administered through a standardized usage protocol, focusing strictly on anatomical placement and defined volume limits. The product is provided as a sterile, viscoelastic injectable gel containing Hyaluronic acid at a concentration of 20 mg/mL, along with 0.3% lidocaine. Administration is restricted to patients who are over the age of 21 for all approved uses.

Official Dosing Volume Limits

The maximum dose that can be administered is strictly specified in the prescribing information. For midface augmentation and the correction of facial folds, the maximum recommended volume is 6.0 mL per treatment session. When treating volume deficit in the dorsal hands, the volume is limited to a maximum of 3.0 mL per hand. For chin augmentation, the maximum total dose, which is inclusive of any necessary touch-up, is 4 mL. If the volume required for optimal hand correction exceeds the single-session limit, a follow-up session is warranted.

Administration Route and Conditions

The official usage protocol specifies precise tissue planes for implantation. For the midface and cheeks, injection is directed into the subcutaneous to supraperiosteal plane (deep injection). By contrast, treatment of facial folds requires placement into the deep dermis to superficial subcutis. The product is strictly for single patient use, must not be resterilized, and should not be mixed with other products before implantation. All procedures must be performed by a healthcare professional experienced in the relevant anatomy.

Recent Clinical Evidence

Research evidence / Overview of studies for Restylane Lyft

Evidence for use in Cheek Augmentation and Midface Contouring

This section will summarize the design of the pivotal, controlled clinical trials used for regulatory evaluation, including the validated volume and contour scales used to assess outcomes in the studied adult population.

Research was evaluated in pivotal clinical trials. These studies were randomized, evaluator-blinded, and controlled, meaning they compared subjects who received the product to a group that received no treatment. The primary goal was to examine changes in midface volume and contouring over time. Outcomes were measured using standardized scales, such as the Medicis Midface Volume Scale. The trials focused on adults who presented with mild to moderate volume loss, including populations with diverse skin pigmentation (Fitzpatrick Skin Types IV, V, and VI).

Findings describe patterns observed in these studies, where a significantly higher rate of subjects met the predefined research criteria for change in volume measurements compared to the untreated control group at all measured time points through 12 months. Studies monitored patterns of change on the Global Aesthetic Improvement Scale (GAIS) as reported by investigators.

Evidence for use in the Correction of Moderate to Severe Facial Folds

This section will review the randomized, evaluator-blinded trial structures that examined the product for correcting facial folds, outlining the specific severity scales and comparator groups utilized in the research.

Studies explored the product for correcting facial folds, particularly the nasolabial folds, often using randomized, evaluator-blinded trial designs. These studies sometimes involved a comparison against another Hyaluronic Acid filler. Researchers monitored changes in the intensity of facial folds using the Wrinkle Severity Rating Scale (WSRS) and the Global Aesthetic Improvement Scale (GAIS). Findings describe patterns where blinded assessments of WSRS scores at the six-month primary assessment indicated a non-inferior pattern when compared to the specific comparator filler used in the trial.

Research Gaps and Areas of Uncertainty

This final section clarifies the key known limitations of the existing research, synthesizing areas where measured change has not been established (e.g., severe cases, unstudied injection methods, or use in non-approved body areas).

Research highlights what has been observed so far in the study of this product and what is still uncertain. The long-term effects are not fully established, as controlled clinical data for the facial indications generally concluded at the one-year mark. Comparative evidence is lacking against the full range of other fillers. Research has not explored patterns of measured change in the following scenarios: treating severe facial retrusion or volume deficits, or use in individuals under the age of 21.

Key Studies & References Clinical Study of Nonanimal Stabilized Hyaluronic Acid (NASHA) for the Augmentation of the Chin Region (Pivotal Trial Supporting Chin Indication, referenced in regulatory materials)

Frequently Asked Questions (FAQ)

Common questions about Restylane Lyft (FAQ)

Q: How long does the effect of Restylane Lyft usually last?

According to official product information, the duration of effect can vary based on the area treated. When Restylane Lyft is used for the cheeks, the benefits generally lasted between two and twelve months. For the treatment of facial wrinkles and folds, the benefits were generally observed for about six months.

Q: Is Restylane Lyft the same as other hyaluronic acid fillers?

Restylane Lyft is an injectable gel containing hyaluronic acid (HA). While HA is the base material for many fillers, Restylane Lyft is a modified, cross-linked form of HA designed to provide specific structural support and lift. Therefore, it is structurally different from some other HA fillers.

Q: Do studies confirm the duration of Restylane Lyft’s effects?

Yes, regulatory information indicates that clinical trials were conducted to evaluate the effects and safety profile over specific periods. The studies confirmed the effectiveness of the product for up to 12 months when used in the cheeks and up to 6 months when used in the hands.

Q: Is Restylane Lyft safe to use for people with autoimmune conditions?

The official product label does not address the use of the product in patients with specific autoimmune conditions. However, regulatory documents advise that the product should be used with caution in patients who are currently undergoing immunosuppressive therapy.

Q: What is the expected recovery time after receiving Restylane Lyft?

Official product information notes that common injection site reactions, such as swelling, redness, and pain, are typically minor or moderate inflammatory symptoms. These effects are generally considered minor to moderate and typically resolved in clinical trials within two weeks.

Q: Can Restylane Lyft be used for people over the age of 65?

Restylane Lyft is officially indicated for use in patients who are over the age of 21 for all approved uses. The regulatory documents do not specify a maximum or upper age limit for treatment.

Q: Do most patients need a touch-up appointment after the first treatment?

Regulatory documents indicate that touch-up treatments were included in the maximum total dose when treating the chin. While this shows touch-ups may be part of a full course of treatment, the documents do not provide a general statement regarding the typical frequency or necessity of touch-up appointments for most patients.

Q: What is the G-Prime rating of Restylane Lyft and what does it mean?

The product is characterized by a high G-Prime (elastic modulus), which describes its viscoelasticity and firmness. This high firmness is a property that contributes to the product’s capacity to provide lift and structural support in the treated areas, such as the midface and hands.

Q: How often do people typically need Restylane Lyft treatments?

The need for repeated treatment is generally related to the duration of effect observed in clinical studies. Official information indicates the product's effectiveness typically lasts about 6 months when used for facial folds and up to 12 months when used for the cheeks.

Q: Does the manufacturer provide information on how to prepare for the procedure?

Yes, official guidance provides information on conditions to consider before treatment. This includes avoiding blood-thinning medications and certain supplements in the preceding three weeks and deferring treatment until the skin has fully healed after certain cosmetic procedures, such as chemical peels.

Q: What is the difference between getting Restylane Lyft in the cheeks versus the hands?

Official regulatory documents specify different maximum dosing limits and injection planes for these areas. The maximum recommended dose for the midface and cheeks is higher than the dose recommended per hand. Also, the injection plane for the face is deep (subcutaneous to supraperiosteal), while the product is injected into the subcutaneous tissue of the dorsal hand.

Q: Does Restylane Lyft look natural?

Clinical trial summaries indicate that the results observed were generally well-received. In the pivotal studies for midface augmentation, investigators and patients reported high satisfaction with the appearance of the treatment, including its natural-looking contour and results.

Q: How does Restylane Lyft compare to non-Hyaluronic Acid fillers in regulatory reviews?

The official regulatory documents detail the product’s safety and effectiveness based on its own clinical trials. They do not contain controlled comparative evidence against the full range of other injectable fillers, including those that are not based on Hyaluronic Acid.

Q: How do doctors manage pain associated with the injection?

Restylane Lyft is supplied with 0.3% lidocaine, a type of local anesthetic, blended directly into the injectable gel formulation. This is included specifically to reduce the discomfort and pain that are associated with the injection procedure.

Q: Is Restylane Lyft considered a cosmetic treatment or a medical device?

Restylane Lyft is officially classified by the regulatory body as a dermal implant intended for aesthetic use. Products of this type are regulated as a medical device.

Q: Is the material used in Restylane Lyft naturally found in the body?

Yes, the active ingredient is Hyaluronic Acid (HA), which is a natural substance already present in the body. Restylane Lyft uses a modified form of HA that is derived from non-animal sources.

Q: What kind of results can a patient realistically expect to see?

In clinical trials, patients saw significant and measurable improvements in volume and contouring in the midface and cheeks, as well as improved volume in the dorsal hands. These outcomes were verified using validated aesthetic scales.

Q: Is it true that Restylane Lyft can be reversed?

Restylane Lyft belongs to the class of Hyaluronic Acid (HA) dermal fillers. HA fillers can be dissolved using an enzyme called hyaluronidase. This enzyme is utilized by healthcare professionals to dissolve the HA material, which can reverse the effects.

Q: Can Restylane Lyft be used if I have had other types of fillers before?

The regulatory documents advise that caution should be used when injecting the product into areas in close proximity to permanent implants, as this carries a potential risk of aggravating latent adverse events.

Q: Are there different versions or formulas of Restylane Lyft?

The product is supplied as a single sterile, viscoelastic injectable gel formulation. Official documents specify this formulation contains Hyaluronic acid at a concentration of 20 mg/mL, along with 0.3% lidocaine.

Q: Are there different kinds of Restylane Lyft for different skin types?

There are no different formulations of the product based on skin type. However, official information notes that patients with pigmented skin may have a higher documented incidence of a side effect known as post-inflammatory hyperpigmentation (skin darkening).

Q: Is it true that the effects last longer in the hands than in the face?

No. Clinical studies comparing the treated areas showed that benefits generally lasted about 6 months for the dorsal hands. By contrast, when the product was used for the cheeks, the effects were shown to last up to 12 months.

Q: Are there any reported cases of delayed adverse events with Restylane Lyft?

Yes, the regulatory documents mention that delayed onset inflammatory papules (small, raised bumps) have been reported following the use of dermal fillers in general.

Q: Is the procedure considered painful by most patients?

Clinical studies specifically examined the effect of the lidocaine component in the formulation. The studies found that the inclusion of lidocaine significantly reduced the pain associated with the injection for up to 1 hour after treatment.

Q: What happens if I get Restylane Lyft and then decide I don't want it anymore?

Since the product is a Hyaluronic Acid (HA) filler, its effects may be reversed. An enzyme called hyaluronidase is available for use by a healthcare professional, which is capable of dissolving the HA material.

Q: Are there risks associated with repeated Restylane Lyft treatments?

The regulatory documents include safety data from clinical trials where subjects received repeat administration of the product. The incidence and severity of adverse experiences were reported to be similar in nature and duration to those recorded during the initial treatment sessions.

How should Restylane Lyft be stored and disposed of?

Storage and Disposal Requirements

Restylane Lyft must be stored under specific environmental constraints to maintain product stability and integrity. The product must be stored at room temperature, up to 25 C (77 F). It is mandatory that the product not be frozen and that it is protected from direct sunlight and excessive heat.

Packaging: The syringe must remain in its original container and must not be used if the package is opened or damaged.
Stability: The product must be used within the expiration date and should be visually inspected for cloudiness or separation before use.
Disposal: After use, the syringe and needle are considered a potential biohazard. They must be discarded immediately in accordance with local, state, and federal requirements for medical waste and sharps disposal. The device is for single patient use only and must not be resterilized.

Restylane Lyft